New Trade Alert: Entest Biomedical, Inc. (ENTB) (OTCMKTS: ENTB)
This has been one of the best years to be an active participant in the OTC markets. And the last 3 months have been getting better and better. We think the final run into year-end might be the best of all.
Our goal is to help you buy that “GI Joe with the Kung Fu Grip” for Christmas this year. And we see ENTB as an incredible opportunity with the potential to get the job done.
The company is starting to get traction in its R&D efforts on the IP front. And it’s working with a tiny float, That’s particularly important in this case given that the stock is starting to see a rapid increase in price per share and average daily trading volume. That spells major squeeze possibilities from present levels.
Symbol: ENTB
Company: Entest Biomedical, Inc. (ENTB)
Quote: http://finance.yahoo.com/q?s=ENTB
Latest News: http://finance.yahoo.com/q/h?s=ENTB+Headlines
Entest Biomedical, Inc. (OTCMKTS: ENTB) is a company that focuses on the development and commercialization of immunotherapeutic therapies for the veterinary market in the United States.
Between 15 million and 20 million dogs are currently kept as pets in the United States. That’s a huge potential market.
And dogs are living longer and longer, which makes us all happy. But living longer means greater likelihood of developing cancer. About 50% of dogs over ten years old develop a cancer-related condition at some point. In the United States, about 6 million dogs are diagnosed with cancer each year. Again, a huge market. Nobody is dominating this space.
Similarly, the cancer incidence rate for cats is estimated to be about 70 to 80 per 10,000 cats. Cancer is less common in cats than in dogs, but can be quite aggressive. Among cats, common cancers include lymphomas and tumors of the subcutaneous tissues, especially the complex feline fibro-sarcoma.
ENTB offers ImenVax family of canine cancer vaccines, such as ImenVax I, a therapeutic for canine cancer, which is involved in isolating tumor cells from the patient and placing the cells into a cell implant device; ImenVax II that utilizes cell lines for sustained release of immunologically relevant cytokines for anti-tumor immune responses; and ImenVax III, a canine cancer vaccine to treat existing tumors through stimulation of immune responses.
The company also provides ENT-576 therapy for the treatment of chronic obstructive pulmonary disease; and acquires and operates veterinary hospitals.
In a recent press release, the company revealed that its wholly owned subsidiary, Zander Therapeutics, has announced the filing of a patent application covering composition of matter and methods of use related to molecules identified in their small molecule program that activate and inhibit NR2F6 (‘Small Molecule Modulators of NR2F6 Activity for Animals’).
That will push them further toward the marketplace. NR2F6 is a molecular switch known as an ‘orphan nuclear receptor’, which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate.
Zander Therapeutics, Inc. has been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize veterinary applications of NR2F6.
Pre-clinical research conducted by Regen BioPharma Inc. (RGBP) and (RGBPP) indicates that by inhibiting NR2F6, cancer stem cells can be converted into normal cells, thus potentially curing the patient of cancer.
If that is confirmed by further research, then everyone associated with this technology is going to be rolling in well-earned mountains of cash. Additionally, activators of NR2F6 have the potential to provide relief from autoimmune diseases such as arthritis.
“This is Zander’s first big step towards creating small molecule therapies that can target the NR2F6 molecule, either inhibiting it to treat cancer or activating it to treat arthritis. Both cancer and arthritis have a huge impact on our pets. There are many milestones to achieve before these therapies are able to treat our pets but, this is a critical first step,” said David Koos, Ph.D., CEO of Zander Therapeutics, Inc.
ENTB shares recent found key support and went through a stage of accumulation. However, the stock has started to rip higher in recent weeks, climbing over 300% in the past several months. In that time, we are seeing the single most important attribute of any bottoming rally: increasing average volume as shares increase in price.
If you think about it, if the price per share doubles (or quadruples in this case) and the volume per day stays the same, that means twice as much money is chasing because the same number of shares or being bought up but at twice the price. Well, ENTB has advanced much further than that, and volume here is up 55% on the move. That shows us that a new and growing market is forming around this stock.
It’s being taken seriously by serious investors. And yet the float is just under 17 million shares. In other words, something has to give!
At this rate, an explosive squeeze is building.
All the pieces are coming together right now: advances in IP status for the company’s R&D investment, a growing market with no blue chip players, a share mechanics that suggest the potential for a serious rally ahead.
About ENTB
ENTB (Entest Biomedical, Inc. (ENTB)) a company that Entest Biomedical focuses on the development and commercialization of immunotherapeutic therapies for the veterinary market in the United States.
ENTB offers ImenVax family of canine cancer vaccines, such as ImenVax I, a therapeutic for canine cancer, which is involved in isolating tumor cells from the patient and placing the cells into a cell implant device; ImenVax II that utilizes cell lines for sustained release of immunologically relevant cytokines for anti-tumor immune responses; and ImenVax III, a canine cancer vaccine to treat existing tumors through stimulation of immune responses.
ENTB also provides ENT-576 therapy for the treatment of chronic obstructive pulmonary disease; and acquires and operates veterinary hospitals. Entest Biomedical was founded in 2008 and is based in La Mesa, California.
What You Need To Know:
- ENTB is getting R&D traction in a huge and undeveloped niche of canine and feline cancer
- ENTB has a small trading float of just 16.87M, which suggests the stock could launch higher on any additional influx of interest.
- ENTB is showing a clear surge in interest, with volume over the last couple weeks tracking 55% above its recent average levels.
- ENTB is coming off an RSI trough under 40, pointing to a massively oversold stock now heading back the other way.
- ENTB just recorded a MACD Bullish explosion, suggesting a technical confirmation of a new upward trend.
Trade Well !
Best Regards,
JT.
Disclaimer: Past performance is not an indicator of future returns. We are not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities.Never make investment decisions based on anything Journal Transcript says. This message is meant for informational and educational purposes only and does not provide investment advice. The report/release/profile/articles is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The paying party may own shares and may liquidate them during the promotional period. Please note have been compensated 2000 USD for advertising on ENTB by an unaffiliated 3rd party Cream Consulting LLC.
PLEASE NOTE WELL: JournalTranscript.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. JOURNALTRANSCRIPT.COMWILL NEVER ACCEPT FREE OR RESTRICTED TRADING SHARES IN ANY COMPANIES MENTIONED at JOURNALTRANSCRIPT.COM&/OR ANY OF OUR SOCIAL NETWORKING AND EMAIL ADVERTISING PLATFORMS.
You are reading this newsletter because you have subscribed via our Opt-In Signup form on our Website. If you have been subscribed by mistake, you may unsubscribe HERE. Our website and newsletter are for Entertainment purposes only. This newsletter is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
We encourage all to read the SEC INVESTOR ALERT before reading our Newsletter.
Release of Liability: Through use of this email and/or website advertisement viewing or using you agree to hold JournalTranscript.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. JournalTranscript.com sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by JournalTranscript.com or an offer or solicitation to buy or sell any security.
We expect to receive future compensation. JournalTranscript.com does not own any shares or positions on this profile. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. JournalTranscript.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and JournalTranscript.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Further, JournalTranscript.com has no advance knowledge of any future events of the profiled companies which includes, but is not limited to, news & press releases, changes in corporate structure, or changes in share structure.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead JournalTranscript.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. JournalTranscript.com is compliant with the Can Spam Act of 2003. JournalTranscript.com does not offer such advice or analysis, and JournalTranscript.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.
In preparing this publication, JournalTranscript.com has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, JournalTranscript.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. JournalTranscript.com is not responsible for any claims made by the companies advertised herein, nor is JournalTranscript.com responsible for any other promotional firm, its program or its structure. We have not been compensated for distribution of this
